You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for New Drug Application (NDA): 012703

✉ Email this page to a colleague

« Back to Dashboard

NDA 012703 describes ELAVIL, which is a drug marketed by Astrazeneca and is included in two NDAs. Additional details are available on the ELAVIL profile page.

The generic ingredient in ELAVIL is amitriptyline hydrochloride. There are thirteen drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the amitriptyline hydrochloride profile page.

Summary for 012703

Tradename:	ELAVIL
Applicant:	Astrazeneca
Ingredient:	amitriptyline hydrochloride
Patents:	0

Medical Subject Heading (MeSH) Categories for 012703

Adrenergic Uptake Inhibitors
Analgesics, Non-Narcotic
Antidepressive Agents, Tricyclic

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET;ORAL			Strength	10MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Approval Date:	Approved Prior to Jan 1, 1982	TE:		RLD:	Yes

Profile for product number 003

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET;ORAL			Strength	25MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Approval Date:	Approved Prior to Jan 1, 1982	TE:		RLD:	Yes

Profile for product number 004

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET;ORAL			Strength	50MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Approval Date:	Approved Prior to Jan 1, 1982	TE:		RLD:	Yes

Expired US Patents for NDA 012703

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca	ELAVIL	amitriptyline hydrochloride	TABLET;ORAL	012703-006	Approved Prior to Jan 1, 1982	3,428,735	⤷ Subscribe
Astrazeneca	ELAVIL	amitriptyline hydrochloride	TABLET;ORAL	012703-001	Approved Prior to Jan 1, 1982	3,428,735	⤷ Subscribe
Astrazeneca	ELAVIL	amitriptyline hydrochloride	TABLET;ORAL	012703-007	Approved Prior to Jan 1, 1982	3,428,735	⤷ Subscribe
Astrazeneca	ELAVIL	amitriptyline hydrochloride	TABLET;ORAL	012703-005	Approved Prior to Jan 1, 1982	3,428,735	⤷ Subscribe
Astrazeneca	ELAVIL	amitriptyline hydrochloride	TABLET;ORAL	012703-004	Approved Prior to Jan 1, 1982	3,428,735	⤷ Subscribe
Astrazeneca	ELAVIL	amitriptyline hydrochloride	TABLET;ORAL	012703-003	Approved Prior to Jan 1, 1982	3,428,735	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.